Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Brian R, Baer"'
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
Min Lu, Pingping Li, Gautam Bandyopadhyay, William Lagakos, Walter E Dewolf, Taylor Alford, Mark Joseph Chicarelli, Lance Williams, Deborah A Anderson, Brian R Baer, Maralee McVean, Marion Conn, Murielle M Véniant, Peter Coward
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88431 (2014)
Glucokinase (GK) is a hexokinase isozyme that catalyzes the phosphorylation of glucose to glucose-6-phosphate. Glucokinase activators are being investigated as potential diabetes therapies because of their effects on hepatic glucose output and/or ins
Externí odkaz:
https://doaj.org/article/6b5ff3c689ce4246a24878968b2d01da
Autor:
Joshua Ballard, Harrah Chiang, James G. Christensen, Kenneth Hee, Tony Pisal Tang, Brian R. Baer, Peter Olson, Henry J. Zecca, David Briere, Mark Joseph Chicarelli, Laurence E. Burgess, Karyn Bouhana, Jill Hallin, Matthew A. Marx, Lauren Hanson, Barbara J. Brandhuber, Michael Burkard, Fell Jay Bradford, Pavel Savechenkov, James F. Blake, John P. Fischer, Guy Vigers, Hicken Erik James, Niranjan Sudhakar, Kevin Davidson, Ronald Jay Hinklin, Macedonio J. Mejia, John Gaudino
Publikováno v:
ACS Medicinal Chemistry Letters. 9:1230-1234
[Image: see text] KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mu
Autor:
Jay B, Fell, John P, Fischer, Brian R, Baer, James F, Blake, Karyn, Bouhana, David M, Briere, Karin D, Brown, Laurence E, Burgess, Aaron C, Burns, Michael R, Burkard, Harrah, Chiang, Mark J, Chicarelli, Adam W, Cook, John J, Gaudino, Jill, Hallin, Lauren, Hanson, Dylan P, Hartley, Erik J, Hicken, Gary P, Hingorani, Ronald J, Hinklin, Macedonio J, Mejia, Peter, Olson, Jennifer N, Otten, Susan P, Rhodes, Martha E, Rodriguez, Pavel, Savechenkov, Darin J, Smith, Niranjan, Sudhakar, Francis X, Sullivan, Tony P, Tang, Guy P, Vigers, Lance, Wollenberg, James G, Christensen, Matthew A, Marx
Publikováno v:
Journal of medicinal chemistry. 63(13)
Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the t
Publikováno v:
Journal of Biological Chemistry. 292:5610-5621
P450 family 4 fatty acid ω-hydroxylases preferentially oxygenate primary C-H bonds over adjacent, energetically favored secondary C-H bonds, but the mechanism explaining this intriguing preference is unclear. To this end, the structure of rabbit P45
Autor:
Jill, Hallin, Lars D, Engstrom, Lauren, Hargis, Andrew, Calinisan, Ruth, Aranda, David M, Briere, Niranjan, Sudhakar, Vickie, Bowcut, Brian R, Baer, Joshua A, Ballard, Michael R, Burkard, Jay B, Fell, John P, Fischer, Guy P, Vigers, Yaohua, Xue, Sole, Gatto, Julio, Fernandez-Banet, Adam, Pavlicek, Karen, Velastagui, Richard C, Chao, Jeremy, Barton, Mariaelena, Pierobon, Elisa, Baldelli, Emanuel F, Patricoin, Douglas P, Cassidy, Matthew A, Marx, Igor I, Rybkin, Melissa L, Johnson, Sai-Hong Ignatius, Ou, Piro, Lito, Kyriakos P, Papadopoulos, Pasi A, Jänne, Peter, Olson, James G, Christensen
Publikováno v:
Cancer discovery. 10(1)
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS
Autor:
Scott Alan Pratt, Patrice Lee, Thomas Daniel Aicher, John Fischer, Kevin Ronald Condroski, Brian R. Baer, Boyd Steven A, Mark D. Chicarelli, Walter C. Voegtli, Walter E. DeWolf, Francis X. Sullivan, Eli M. Wallace, Nickolas A. Neitzel, Lance A. Williams, Ronald Jay Hinklin, Turner Timothy M, Ajay Singh, Gary P. Hingorani, Michele Frank
Publikováno v:
Bioorganicmedicinal chemistry. 28(1)
Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to hav
Autor:
James G. Christensen, Macedonia J. Mejia, Tony Pisal Tang, Joshua Ballard, Pavel Y. Savechenkov, Mark Joseph Chicarelli, Guy Vigers, Niranjan Sudhakar, James F. Blake, Peter D. Olson, Brian R. Baer, David Briere, Matthew A. Marx, Fell Jay Bradford, Michael R. Burkhard, Karyn Bouhana, Laurence E. Burgess, Jill Hallin, Harrah Chiang, John P. Fischer
Publikováno v:
Molecular Cancer Research. 18:B30-B30
The ability to effectively target mutated KRAS has remained elusive despite decades of research. By solving a highly informative set of ligand-complexed co-crystal structures coupled with iterative structure-based drug design, substituted tetrahydrop
Autor:
David Briere, Lauren Hargis, James G. Christensen, Matthew A. Marx, Jill Hallin, Fell Jay Bradford, Lars D. Engstrom, Niranjan Sudhakar, Peter D. Olson, Andrew Calinisan, Michael R. Burkhard, John P. Fischer, Harrah Chiang, Ruth Aranda, Brian R. Baer
Publikováno v:
Molecular Cancer Research. 18:B23-B23
KRAS G12C is a driver mutation and the most frequent KRAS mutation in lung cancer. The ability to effectively target mutated KRAS has remained elusive despite decades of research. A structure-based drug design discovery program identified mutant-sele